Campbell & CO Investment Adviser LLC Grows Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Campbell & CO Investment Adviser LLC increased its holdings in Zimmer Biomet by 611.4% in Q1, now owning 19,634 shares valued at approximately $2.22 million.
• Several institutional investors have significantly increased their positions, including Ameriprise Financial with a 236.0% increase and JPMorgan Chase with a 251.3% increase in Q1.
• Zimmer Biomet reported $2.07 earnings per share for its latest quarter, exceeding analysts' expectations, and has set a fiscal year 2025 guidance of 8.100-8.300 EPS.

Campbell & CO Investment Adviser LLC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 611.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,634 shares of the medical equipment provider's stock after acquiring an additional 16,874 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Zimmer Biomet were worth $2,222,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Quantitative Investment Management LLC acquired a new position in Zimmer Biomet during the first quarter worth $2,317,000. Dodge & Cox raised its holdings in Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider's stock worth $2,214,305,000 after buying an additional 446,018 shares during the last quarter. AlphaQuest LLC acquired a new position in Zimmer Biomet during the first quarter worth $579,000. Allstate Corp raised its holdings in Zimmer Biomet by 19.1% during the first quarter. Allstate Corp now owns 7,537 shares of the medical equipment provider's stock worth $853,000 after buying an additional 1,208 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after buying an additional 3,208,596 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Raymond James Financial upped their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. JMP Securities lowered their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Royal Bank Of Canada upped their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Robert W. Baird reduced their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $111.44.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Performance

ZBH traded down $1.74 during trading on Thursday, hitting $105.05. 1,092,866 shares of the company traded hands, compared to its average volume of 2,037,245. The firm has a market cap of $20.81 billion, a P/E ratio of 25.56, a price-to-earnings-growth ratio of 2.12 and a beta of 0.68. The stock's fifty day moving average is $96.50 and its 200 day moving average is $99.39. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.